Home › Ovarian Epithelial Carcinoma › Pennsylvania › Pittsburgh
Ovarian Epithelial Carcinoma clinical trials in Pittsburgh, PA
3 studies for Ovarian Epithelial Carcinoma are looking for participants at sites in and around Pittsburgh (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RecruitingPhase 2
- West Penn Hospital /ID# 276028, Pittsburgh
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
RecruitingPhase 1
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
RecruitingPhase 1
- UPMC Hillman Cancer Center, Pittsburgh
Ovarian Epithelial Carcinoma trials in other cities
- New York City, NY10 studies
- Boston, MA8 studies
- Durham, NC8 studies
- Cleveland, OH7 studies
- Houston, TX7 studies
- Baltimore, MD6 studies
- Chicago, IL6 studies
- Philadelphia, PA6 studies
- Salt Lake City, UT6 studies
- Edison, NJ5 studies
- Los Angeles, CA5 studies
- Minneapolis, MN5 studies
Other studies in Pittsburgh
- Non-Small Cell Lung Cancer47 studies
- Cancer (all types)42 studies
- Breast Cancer42 studies
- Ovarian Cancer32 studies
- Colorectal Cancer31 studies
- Metastatic Cancer31 studies
- Melanoma31 studies
- Endometrial Cancer24 studies
- Lung Cancer24 studies
- Head and Neck Squamous Cell Carcinoma23 studies
- Prostate Cancer23 studies
- Depression22 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.